Smokers appear to face a reduced risk of catching COVID-19. Does their deadly habit offer them some sort of protection? CRISPR crops may mimic nature, but that doesn't mean they should evade strict regulation, a team of researchers argues. After losing several expensive lawsuits, Bayer has finally successfully defended its Roundup weedkiller against a claim that it causes cancer.
Join geneticist Kevin Folta and GLP contributor Cameron English on this episode of Science Facts and Fallacies as they break down these latest news stories:
* Smokers are less likely to get COVID: French researchers explore whether nicotine might prevent transmission
A new study adds to the growing body of epidemiological evidence that smokers are less likely to catch COVID-19. In a region of France with high smoking rates, the researchers found that non-smokers faced a 400 percent higher risk of illness than smokers. Does something in tobacco smoke, perhaps nicotine, offer protection against the deadly SARS-COV-2 virus?
* Viewpoint: CRISPR gene edited crops ‘mimic nature’ — but that doesn’t mean they shouldn’t be regulated
Many advocates of CRISPR gene editing have defended the technology, in part, by arguing that it mimics natural processes that induce mutations in the DNA of plants and animals. Critics of the new breeding technique aren't impressed. Who cares, they ask, if CRISPR approximates nature? That has no bearing on the risk the technology poses and, as a result, how it should be regulated. Nuclear weapons are natural in many ways, critics claim in comparison, yet we tightly regulate them. Does this argument stand up to scrutiny?
* Bayer claims first victory in glyphosate litigation, as jury rejects claim weedkiller caused a child’s non-Hodgkin’s Lymphoma
Bayer has been pummeled in court over the last few years. Three plaintiffs have convinced as many juries that the company's glyphosate-based Roundup weedkillers caused their non-Hodgkin's Lymphoma, though there is no evidence to support that charge. Those losses, two of which Bayer has appealed to the US Supreme Court, forced the company to settle 96,000 similar lawsuits.
Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.
SIGN UP
Earlier this month, however, Bayer won its first case.